ZUMA-1
Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 101 patients with refractory aggressive large B-cell lymphoma, axicabtagene ciloleucel (anti-CD19 CAR-T) produced durable complete remissions in a setting with no effective standard therapy.
N
101
Design
Single-arm phase 1/2
Endpunkt
Objective response rate
Relevanz
2
ErgebnisORR 82%; CR 58%. 5-yr OS 42.6%; disease-specific survival 51%.
Neelapu SS, et al. N Engl J Med. 2017;377(26):2531-2544; Neelapu SS, et al. Blood. 2023;141(19):2307-2315. 10.1056/NEJMoa1707447
Diskussion & Kritik
First CAR-T approval for adult lymphoma. ZUMA-7 later moved CAR-T to second-line therapy; cytokine release syndrome and ICANS remain the defining toxicities.